Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: May 9, 2008

(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

001-38122

59-3410522

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification Number)


13700 Progress Blvd		32615
(Address of principal executive offices)		(Zip Code)

386-418-4018

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

OTHER EVENTS

On May 9, 2008, Oragenics, Inc. (the “Company”) issued a press release regarding the expected test marketing of its oral probiotic product, Probiora3 to consumers to improve breath and whiten teeth. The press release is attached to this report as Exhibit 99.1 and incorporated by reference herein.

Item 9.01

FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.


Number		Description
99.1		Press Release dated May 9, 2008

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 9^th day of May, 2008.


ORAGENICS, INC. (Registrant)

BY:		/s/ Stanley Stein
		Stanley Stein President and Chief Executive Officer